Jennifer Strople1, Glenda Lovell, James Heubi. 1. Division of Gastroenterology, Hepatology, and Nutrition, Children's Memorial Hospital, Chicago, IL 60614, USA. jstrople@childrensmemorial.org
Abstract
BACKGROUND AND OBJECTIVE: Prothrombin time (PT), a surrogate marker of vitamin K deficiency, may underestimate the prevalence of vitamin K deficiency in cholestatic liver disease. This study investigated the frequency of vitamin K deficiency in children and adults with cholestatic liver disease by determining plasma protein induced in vitamin K absence II (PIVKA-II), and assessed the relation between plasma PIVKA-II levels and markers of cholestasis, measured PT, international normalized ratio (INR), serum undercarboxylated osteocalcin (ucOC), serum vitamins A and E, and serum 25-hydroxyvitamin D levels. PATIENTS AND METHODS: Blood was collected from patients with cholestatic liver disease for liver biochemistries, PT, INR, bile acids, 25-hydroxyvitamin D, vitamin A, vitamin E, ucOC, and PIVKA-II. RESULTS: Thirty-one patients were enrolled (age range 0.5-54 years, median age 5.7 years, 17 females). Nine patients (29%) had increased INRs, whereas 21 (68%) had elevated plasma PIVKA-II levels. All patients with increased INRs had increased plasma PIVKA-II. Fifteen of 21 patients with increased plasma PIVKA-II were receiving supplemental vitamin K therapy (range 7.8-700 mug/kg/day). Plasma PIVKA-II levels were positively correlated with serum conjugated bilirubin, bile acids, aspartate aminotransferase, alanine aminotransferase, PT, INR, and serum ucOC (P <or= 0.02) and negatively correlated with serum 25-hydroxyvitamin D levels (P = 0.01). Twenty-two patients (71%) had vitamin D deficiency, 9 patients (29%) had vitamin A deficiency, and 2 patients (6%) had vitamin E deficiency. CONCLUSIONS: Despite vitamin K supplementation, elevation of plasma PIVKA-II suggesting ongoing vitamin K deficiency is common in cholestatic liver disease. Better strategies for vitamin K supplementation and dosing guidelines are needed.
BACKGROUND AND OBJECTIVE:Prothrombin time (PT), a surrogate marker of vitamin K deficiency, may underestimate the prevalence of vitamin K deficiency in cholestatic liver disease. This study investigated the frequency of vitamin K deficiency in children and adults with cholestatic liver disease by determining plasma protein induced in vitamin K absence II (PIVKA-II), and assessed the relation between plasma PIVKA-II levels and markers of cholestasis, measured PT, international normalized ratio (INR), serum undercarboxylated osteocalcin (ucOC), serum vitamins A and E, and serum 25-hydroxyvitamin D levels. PATIENTS AND METHODS: Blood was collected from patients with cholestatic liver disease for liver biochemistries, PT, INR, bile acids, 25-hydroxyvitamin D, vitamin A, vitamin E, ucOC, and PIVKA-II. RESULTS: Thirty-one patients were enrolled (age range 0.5-54 years, median age 5.7 years, 17 females). Nine patients (29%) had increased INRs, whereas 21 (68%) had elevated plasma PIVKA-II levels. All patients with increased INRs had increased plasma PIVKA-II. Fifteen of 21 patients with increased plasma PIVKA-II were receiving supplemental vitamin K therapy (range 7.8-700 mug/kg/day). Plasma PIVKA-II levels were positively correlated with serum conjugated bilirubin, bile acids, aspartate aminotransferase, alanine aminotransferase, PT, INR, and serum ucOC (P <or= 0.02) and negatively correlated with serum 25-hydroxyvitamin D levels (P = 0.01). Twenty-two patients (71%) had vitamin D deficiency, 9 patients (29%) had vitamin A deficiency, and 2 patients (6%) had vitamin E deficiency. CONCLUSIONS: Despite vitamin K supplementation, elevation of plasma PIVKA-II suggesting ongoing vitamin K deficiency is common in cholestatic liver disease. Better strategies for vitamin K supplementation and dosing guidelines are needed.
Authors: Duy T Dao; Lorenzo Anez-Bustillos; Adam M Finkelstein; Paul D Mitchell; Alison A O'Loughlin; Gillian L Fell; Meredith A Baker; Alexis K Potemkin; Kathleen M Gura; Mark Puder Journal: JPEN J Parenter Enteral Nutr Date: 2019-07-07 Impact factor: 4.016
Authors: Benjamin L Shneider; John C Magee; Jorge A Bezerra; Barbara Haber; Saul J Karpen; Trivellore Raghunathan; Philip Rosenthal; Kathleen Schwarz; Frederick J Suchy; Nanda Kerkar; Yumirle Turmelle; Peter F Whitington; Patricia R Robuck; Ronald J Sokol Journal: Pediatrics Date: 2012-08-13 Impact factor: 7.124
Authors: Veena L Venkat; Benjamin L Shneider; John C Magee; Yumirle Turmelle; Ronen Arnon; Jorge A Bezerra; Paula M Hertel; Saul J Karpen; Nanda Kerkar; Kathleen M Loomes; Jean Molleston; Karen F Murray; Vicky L Ng; Trivellore Raghunathan; Philip Rosenthal; Kathleen Schwartz; Averell H Sherker; Ronald J Sokol; Jeffrey Teckman; Kasper Wang; Peter F Whitington; James E Heubi Journal: J Pediatr Gastroenterol Nutr Date: 2014-12 Impact factor: 2.839
Authors: Agozie C Ubesie; James E Heubi; Samuel A Kocoshis; Carol J Henderson; Adam G Mezoff; Marepalli B Rao; Conrad R Cole Journal: J Pediatr Gastroenterol Nutr Date: 2013-09 Impact factor: 2.839